海创药业HP518片联合抗肿瘤药物治疗晚期前列腺癌临床试验获批

Core Viewpoint - Haichuang Pharmaceutical has received approval from the National Medical Products Administration of China for clinical trials of HP518 tablets in combination with anti-tumor drugs for the treatment of advanced prostate cancer [1] Group 1: Company Developments - The company announced the approval of the clinical trial for HP518 tablets, which will be conducted in China, Australia, and the United States [1] - Currently, there are no similar products approved for market release in both domestic and international markets [1]